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Abstract
Coronavirus disease 19 (COVID-19) has dramatically altered everyday life, including
the field of Alzheimer’s disease (AD) research. This perspective article explores some
of the ways in which COVID-19 has already impacted the field, anticipates some of
the long-lasting effects, and explores strategies for addressing current and future
needs. Areas of impact include study integrity, regulatory and industry issues, and
participant engagement. Proposed strategies for addressing these challenges include
analytic methods to deal with large degrees of missing data and development of
patient-centered, user-friendly, remote data collection tools and assessments.We also
highlight the importance of maintaining participant well-being as a first and constant
priority.
The coronavirus disease 19 (COVID-19) pandemic has disrupted
everyday life around the globe.1 For those of us working in the area of
Alzheimer’s disease (AD) prevention and treatment, it is important to
take stock of the immediate impact, anticipate some ongoing effects,
respond to current needs, and anticipate future challenges. This letter
is focused on the impact of COVID-19 on clinical research in popula-
tions of individuals at risk for or with dementia. Although several of
these challenge areas were addressed briefly in a recent Alzheimer’s &
Dementia editorial, we expand upon them here and offer thoughts for a
path forward.2
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1 STUDY INTEGRITY
The immediate impact of COVID-19 includes analytic challenges with
ongoing studies that, due to requirements for social distancing, will
now have inconsistent adherence to protocols as designed with visit
schedules and medication and intervention adherence all more fluid
than in ideal circumstances.3 Addressing this challenge will require
skilled statisticians using available, and perhaps novel, analytic meth-
ods to ensure thatwedonot incorrectly conclude that a new treatment
is ineffective due tomidstream pauses and interruption of drug dosing.
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Although we are all still reeling from the rapid onset of this crisis, we
also need to consider the possibility that higher than anticipated study
attritionmay lead to failed trials.
2 REGULATORY AND INDUSTRY ISSUES
It remains unclear, but of critical importance, howwill regulatory agen-
cies consider the data stemming fromAD trials interrupted by COVID-
19. In the United States, the U.S. Food and Drug Administration (FDA)
has issued statements of assurance that they understand the need
for study interruptions and protocol deviations, but how they will
resolve the impact of such study conduct on future regulatory deci-
sions remains unknown. Given these considerations, industry sponsors
are currently weighing the cost/risk/benefit ratios of continuing ongo-
ing studies or simply halting trials altogether and beginning anew once
the crisis has abated.
3 IMPACT ON CURRENT PARTICIPANTS AND
PROSPECTIVE RECRUITMENT
Wehaveencounteredmixed feelings amongparticipants; someare vol-
untarily pulling back from their research engagement in the face of
the immediate threat the COVID-19 crisis posits to their health and
well-being and others wish to push on as they understand AD’s pro-
found and ongoing impact. Today’s social distancing requirements may
have long-lasting effects, including lingering apprehension about social
contact and a shift from altruistic research motivations to choices to
remain more isolated to protect one’s own health. The limited pool of
participants willing to engage in AD research may become even more
limited in the future if heavy demands are placed on research activi-
ties within centers that may be perceived in the future as hotspots for
contagion. Maximal impacts for such societal change would be seen in
the area of invasive study procedures and biomarker collections, which
are critical for the conduct of state-of-the-art clinical trial research
in the area of preclinical, prodromal, and even fulminant AD. Further-
more, withmorbidity, mortality, and economic hardship disproportion-
ately affecting those who are already disadvantaged, we anticipate
increased challenges engaging diverse and underrepresented individu-
als in research, raising concerns for generalizability.4 These challenges
and the need for innovation will coexist within an uncertain funding
landscape as we deal with the global economic fallout from this pan-
demic.
4 CHANGES WE HOPE TO SEE IN THE CLINICAL
TRIAL LANDSCAPE
After we move past the most acute period of COVID-19, the effects
on AD clinical research will persist. Because the need for remote
RESEARCH INCONTEXT
1. Systematic Review: Due to the recent and rapid emer-
gence of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), the virus that causes coronavirus dis-
ease 19 (COVID-19) and its impact, this perspective piece
incorporates the expert opinions of the authors and their
careful consideration of the areas of Alzheimer’s disease
(AD) research likely to be affected now and moving for-
ward, as well as ways in which the field can adapt. A brief
PubMed review for relevant articles paralleled this effort.
2. Interpretation: This perspective piece highlights impor-
tant considerations and a path forward to help transform
the challenges that COVID-19 brings to AD research into
constructive change.
3. Future Directions: Moving forward it will be important
to evaluate how proposed changes affect participant and
research outcomes and whether they can make the field
more resilient to future challenges.
data collection has been clearly demonstrated, we anticipate an
increased investment in the development of remote tools and assess-
ments that will enable gathering of clinical and neuropsychological
data from the participant’s home. This is a welcome move toward
increased participant-centeredness. This transition, however, will
be accompanied by additional challenges to ensure that we do not
exacerbate existing health disparities by leaving those without access
to technology, whichmay be required for remotemonitoring activities,
behind.
5 CONCLUSION
Webelieve the field can rise tomeet the current challenges, transform-
ing the need for social distancing into an impetus for positive change.
These potential beneficial changes in trial design, statistical method-
ologies to address even large swaths ofmissing data, changes in regula-
tory rules and oversight, and the development of new tools for remote
assessment of cognition and decline are critical priorities for the field.
These areas provide a real opportunity for constructive change in the
face of what is otherwise a devastating crisis.
While responding to and anticipating these challenges, we need to
keep our participants at the forefront of our thoughts. Demonstrating
that protecting participants is a priority will go a long way to building
andmaintaining trust in research. In contrast, if we put research needs
above participant health we will have significant distrust to overcome
in the future. Our efforts today can dramatically improve the clinical
trial landscape as wemove forward.
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